Bladder-Sparing Treatment for Bladder Cancer With Variant Cell Types
Tests chemotherapy followed by chemotherapy and radiation in adults with muscle-invasive bladder cancer.
Key facts
- Who runs it
- Leslie Ballas
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 16 Jan 2026
- Expected to end
- Dec 2030
- Type of study
- Interventional
- Treatments tested
- Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
- Record updated
- 6 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with muscle invasive bladder cancer that has a variant (non-pure urothelial) cell type, who are having chemotherapy first, then chemotherapy with radiation to try to keep the bladder.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Muscle invasive bladder cancer with variant histology, stage cT2-T4N0M0, confirmed by TURBT and CT of chest, abdomen and pelvis and/or PET
- Earlier treatment
- Cannot have had earlier systemic therapy for muscle invasive bladder cancer or earlier radiation to the pelvis
Main reasons for not taking part
- Diffuse cis (carcinoma in situ) on pathology
- Fluid backup in both kidneys (bilateral hydronephrosis); only one side is allowed
- Earlier radiation to the pelvis
- Earlier systemic therapy for muscle invasive bladder cancer
- Another cancer at the same time (a cancer more than 5 years ago is allowed if there is no sign of disease)
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Documented diagnosis of MIBC with variant histology, cT2-T4N0M0, confirmed by TURBT and CT C/A/P and/or PET
- Written informed consent obtained from subject and ability for subject to comply with the requirements of the study
Who cannot take part
- Prior radiotherapy to the pelvis
- History of systemic therapy for MIBS
- Presence of concurrent cancer (remote history of cancer (>5 years) allowed if the patient is without evidence of disease)
- Evidence of diffuse cis on pathology
- Presence of bilateral hydronephrosis (if hydronephrosis is present, can only be unilateral)
Where in United States
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Clinical Trial Recruitment NavigatorTaking people
About the trial
What the trial wants to find out
This is a Phase II, single cohort study designed to evaluate outcomes in patients with muscle invasive bladder cancer (MIBC) with variant histology who receive neoadjuvant chemotherapy (NAC) with or without immunotherapy (IO) followed by trimodal therapy (TMT). Enrolled patients will undergo at least 3 cycles of NAC +/- IO (oncologist's choice) followed by a four- or six-week course of concurrent standard of care chemotherapy and radiation therapy. These patients will be compared with historical controls of patients with a diagnosis of pure urothelial carcinoma who have undergone TMT. This study has been designed to test the hypothesis that variant histology TMT can be delivered within 45 days of NAC +/- IO and is therefore a viable option in patients who are risk of systemic disease spread.
The group in the trial
- Single ArmTreatment being tested
Neoadjuvant chemotherapy followed by trimodal therapy consisting of TURBT followed by concurrent chemotherapy with radiation therapy
Treatment: Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- IIT2023-13-BALLAS-VHTMT: Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
- Plain-language title
- Bladder-Sparing Treatment for Bladder Cancer With Variant Cell TypesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 August 2026